 safeti pharmacokinet subject aid aids-rel complex phase phase studi safeti pharmacokinet singl intraven infus subject aid aids-rel complex arc activ ingredi trichosanthin trichosanthin china activ drug community-initi treatment program patient hiv infect eighteen subject aid arc subject toler toxic immunolog virolog paramet administr notabl toxic except subject sever neurolog advers reaction consist chang lymphocyt popul hiv antigen level serum concentr compar concentr antivir activ vitro suffici durat antiretrovir effect further studi pharmacodynam properti optim dose schedul molecul use treatment hiv infect